Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02722538 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer
A Phase 1 study, sponsored by Taris Biomedical.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT02722538 is a Phase 1 study that has completed, run by Taris Biomedical. The registered enrollment target is 23 participants.
The verdict
NCT02722538, a Phase 1 study, has completed, sponsored by Taris Biomedical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if TAR-200, an investigational drug-delivery system, is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) between diagnosis and radical cystectomy (RC).
Interventions
- DRUG Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2016-05-31 |
| Est. Completion | 2019-05-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02722538
The ClinicalTrials.gov registry entry for NCT02722538 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taris Biomedical, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 is the first listed.
NCT02722538 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02722538 about?
NCT02722538 is a clinical study titled "Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer". The purpose of this study is to determine if TAR-200, an investigational drug-delivery system, is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) between diagnosis and radical cystectomy (RC).
What is the current status of trial NCT02722538?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2016-05-31. Estimated completion is 2019-05-02.
What interventions are being tested in trial NCT02722538?
The interventions under investigation include: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 (DRUG).
Who is sponsoring clinical trial NCT02722538?
This trial is sponsored by Taris Biomedical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.